US FDA Could Require Pediatric Cancer Drug Combo Studies Under Amended User Fee Bill

House Energy & Commerce Committee adds Give Kids a Chance Act to user fee reauthorization package during markup. Bill was modified to exclude provision giving the FDA authority to require preclinical studies.

Pediatric cancer
Pediatric studies of investigational cancer drug combinations could be required by FDA under amended user fee bill • Source: Shutterstock

The US Food and Drug Administration would be authorized to require companies developing new combinations of cancer drugs to conduct pediatric studies under an amendment to user fee reauthorization legislation adopted by the House Energy & Commerce Committee.

At its 18 May markup of the measure, the committee voted unanimously in favor of an amendment by Rep. G.K....

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Clinical Trials

More from R&D

  • India Tightens Oversight Of CROs With Mandatory Registration

     
    • By 

    Contract research organizations (CROs) in India must gear up to comply with new registration requirements coming into effect in April 2025 that aim to enhance the quality and integrity of clinical trials, as well as of any bioavailability and bioequivalence studies conducted by them.

  • Clinical Trial Diversity Action Plans Need Timely FDA Feedback, Groups Say

     
    • By 

    The agency also should explain the potential consequences for sponsors if enrollment goals are not met, stakeholders say in comments on the DAP draft guidance. Some commenters urged the FDA to apply waiver criteria flexibly, especially for rare diseases.

  • How To Decarbonize Pharma R&D

     

    As the planet heats up and sea levels rise, the need to reduce carbon emissions is becoming ever more urgent. The life sciences industry is just one of many that are looking to cut the carbon it produces.